aibioLisata cuts 72% of staff after failed Kuva buyout, then merges with Marea
Tickers LSTA
Kuva Labs could not raise the money to complete its $4.00 tender offer for Lisata. Lisata then cut about 72% of its staff, and on Sept 17 it bought Marea with a $225 million private placement that heavily dilutes existing holders.
Key facts
- Company
- Lisata Therapeutics, Inc. (NASDAQ: LSTA)
- News type
- Distress
- Primary source
- Lisata Therapeutics (SEC Form 8-K)
Lisata Therapeutics said in an Aug 3 8-K that its board approved a reduction in workforce of about 72%, effective immediately. The company expects about $1.2 million of costs for severance pay and other termination benefits, to be incurred through the quarter ending September 30. The chief medical officer, Dr. Kristen K. Buck, was terminated the same day. Under her employment agreement, she is entitled to 12 months of base salary and target bonus, plus COBRA premiums for up to 12 months, subject to a release.
The failed Kuva deal
Lisata agreed on March 6 to be acquired by Kuva Labs through a tender offer. As amended, the price was $4.00 per share in cash, plus a contingent value right worth up to $3.00 in two contingent payments. The initial terms in March had been $5.00 in cash plus a $1.00 contingent payment. The offer expired on July 20 without Kuva accepting any shares. In a July 24 8-K, Lisata said Kuva had been unable to obtain sufficient financing to fund the offer and had failed to accept and pay for the tendered shares. Lisata terminated the merger agreement and said it would return the tendered shares to holders.
Kuva owes Lisata a termination fee of $2,000,000 under the merger agreement. Lisata reserves the right to seek damages for willful breach, but it warned that there can be no assurance it will obtain them, given its limited financial resources to fund litigation. On July 31, Lisata sued Kuva Labs in the Delaware Court of Chancery. The August filing also records a $200,000 cash retention bonus for James Nisco, Senior Vice President, Finance and Treasury and Chief Accounting Officer, payable if he stays through December 31, 2026.
Marea and the placement
On Sept 17, a step the headline names, Lisata acquired Marea Therapeutics and agreed to sell Series C non-voting convertible preferred stock in a private placement. Gross proceeds are expected to be about $225 million, before placement agent and other offering expenses. Lisata's release says the financing is projected to fund operations into 2028. Its 8-K names Jefferies, Leerink Partners, Guggenheim Securities, Cantor and LifeSci Capital as placement agents, H.C. Wainwright as its financial advisor, and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. as its legal counsel. Leerink Partners advised Marea, Goodwin Procter LLP was Marea's counsel, and Cooley LLP advised the placement agents.
The programs Lisata is buying are early. Marea's MAR001/005 is in a Phase 2b trial for severe hypertriglyceridemia, and MAR002 is advancing to a Phase 2 study in acromegaly. Both are expected to report topline data in the fourth quarter of 2027. Lisata's own lead, certepetide, is described in its 10-K as the subject of several Phase 2 studies in solid tumors.
Lisata issued 1,793,129 shares of common stock and 211,365.213 shares of Series C preferred stock to Marea's stockholders. Each Series C share converts into 1,000 common shares, but only after Lisata's stockholders approve the conversion under Nasdaq rules. The conversion would represent more than 20% of the outstanding common stock and would result in a change of control.
Cash, losses and dilution
Lisata's June 30 balance sheet showed cash and cash equivalents of $10,443 thousand, and management had concluded there is substantial doubt about the company's ability to continue as a going concern. For the six months ended June 30, Lisata reported a net loss of $7,418 thousand, against $9,383 thousand a year earlier. Its 10-K reported a net loss of $16.6 million for 2025, down from $20.0 million in 2024, and cash used in operations of $15.9 million for 2025.
The dilution is large. The Sept 17 8-K estimates that, on a fully diluted basis and after the financing, pre-transaction Lisata stockholders would hold about 2.39% of the common stock. Marea's former equityholders would hold about 59.54%, and the new investors about 38.07%. The placement includes RA Capital Management, Forbion, Third Rock Ventures, Alpha Wave and Perceptive Advisors, among other institutions.
Lisata's annual meeting is set for Nov 9, 2026, and stockholders will vote on the Series C conversion there. Until then, the preferred shares cannot convert.